Core Viewpoint - A securities class action lawsuit has been filed against CarMax, Inc. for allegedly making false and misleading statements regarding its growth prospects during the Class Period from June 20, 2025, to November 5, 2025 [1][2]. Summary by Sections Allegations Against CarMax - The complaint claims that CarMax's management overstated the company's growth potential, attributing earlier growth in the 2026 fiscal year to temporary factors related to customer behavior influenced by tariff speculation [2]. - It is alleged that the positive statements made by the defendants about CarMax's business operations and future prospects were materially misleading and lacked a reasonable basis [2]. Lead Plaintiff Process - Investors in CarMax have until January 2, 2026, to apply to be appointed as lead plaintiff representatives in the class action lawsuit [3]. - The lead plaintiff will represent the interests of all class members and will select legal counsel to direct the litigation [3]. Law Firm Background - Kessler Topaz Meltzer & Check, LLP is a prominent law firm specializing in securities-fraud class actions and has a history of significant recoveries in securities litigation [4]. - The firm represents both individual and institutional investors and has received numerous accolades for its work in the field [4].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about the operational readiness of its next-generation device, the Inspire V, leading to significant financial losses for investors [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its operational readiness for the Inspire V launch, stating it was ready for a full commercial rollout, while concealing critical operational failures [3][4]. - Key undisclosed operational issues included delays in Medicare claims processing software updates, which only took effect on July 1, 2025, causing revenue bottlenecks [4]. - An excess inventory of the older Inspire IV device negatively impacted demand for the new Inspire V product, necessitating an inventory "burn down" [4]. - Many treatment centers had not completed the necessary training and onboarding for the new device, further hindering the launch [4]. Group 2: Financial Consequences - The alleged operational failures led Inspire Medical to cut its 2025 earnings per share (EPS) guidance by over 80%, resulting in a significant stock price drop of $42.04 per share, equating to a 32.4% decline in value [4][5]. - The lawsuit highlights that the stock collapse was attributed to management prioritizing a narrative of seamless transition over the actual operational challenges faced [5]. Group 3: Legal and Investigative Actions - Hagens Berman, the law firm leading the investigation, is encouraging investors who suffered losses during the class period from August 6, 2024, to August 4, 2025, to contact them before the January 5, 2026, lead plaintiff deadline [2][3]. - The firm is particularly focused on the concealment of the Medicare claims software failure and the inventory issues related to the Inspire IV device [5].

Core Viewpoint - A securities class action lawsuit has been filed against Firefly Aerospace Inc. for allegedly making false and misleading statements regarding its business operations and growth prospects during its IPO and subsequent period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Firefly's common stock during the IPO on August 7, 2025, and securities acquired between August 7, 2025, and September 29, 2025 [1]. - The deadline for investors to be appointed as lead plaintiffs is January 12, 2026 [4]. Group 2: Allegations Against Firefly - The complaint alleges that Firefly overstated the demand and growth prospects for its Spacecraft Solutions offerings [3]. - It is claimed that the Alpha rocket program did not meet its operational readiness and commercial viability as represented [3]. - As a result of these issues, the statements made by Firefly regarding its business and prospects were materially false and misleading [3].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for allegedly misrepresenting its product performance and integrity, leading to investor losses during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Stride securities from October 22, 2024, to October 28, 2025 [1][2]. - Investors have until January 12, 2026, to seek appointment as lead plaintiff representatives [2]. - Allegations include overstating enrollment figures, reducing staff costs beyond legal limits, failing to meet compliance standards, and losing key enrollments [3]. Group 2: Company Background - Stride, Inc. is an education technology company based in Reston, Virginia, providing digital learning programs and instructional support to public and private schools [2]. - The company assured investors of its commitment to personalized learning while allegedly failing to deliver on these promises [3].

Core Viewpoint - Purcell & Lefkowitz LLP is investigating Datavault AI Inc. to determine if the company's directors breached their fiduciary duties related to recent corporate actions [1] Group 1: Investigation Details - The investigation is on behalf of Datavault AI Inc.'s shareholders [1] - The focus is on potential breaches of fiduciary duties by the company's directors [1] Group 2: Shareholder Information - Shareholders interested in more information about their rights and options can visit the law firm's website [2] - Contact details for Robert H. Lefkowitz, Esq. are provided for shareholders to discuss the case at no cost [2] Group 3: Law Firm Background - Purcell & Lefkowitz LLP specializes in representing shareholders affected by securities fraud and corporate misconduct [3] - The firm emphasizes its commitment to shareholder rights nationwide [3]

FCX NOTIFICATION: BFA Law Notifies Freeport-McMoRan Inc. Investors of the Pending Class Action Lawsuit and Upcoming January 12 Legal DeadlineDecember 10, 2025 7:18 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 10, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company's senior executives for securities fraud after significant ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [2][4]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [5]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was not the case as the company failed to prepare clinicians and payors adequately, leading to delays in adoption [6][7]. - The launch of Inspire V faced significant challenges, including weak demand due to customers having excess inventory of older devices and delays in training and software updates necessary for billing [8][9]. Stock Performance - Following the announcement of an "elongated timeframe" for the Inspire V launch and a reduction in 2025 earnings per share guidance by over 80%, Inspire's stock price dropped by $42.04, or more than 32%, from $129.95 to $87.91 per share between August 4 and August 5, 2025 [8][9].

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. for securities fraud following a significant drop in stock price attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Maryland, titled Jason Cap v. CarMax, Inc., et al., No. 1:25-cv-03602, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 2, 2026, to request to be appointed to lead the case [3]. Group 2: Reasons for the Lawsuit - CarMax is accused of misleading investors regarding the demand for its vehicles, which was allegedly inflated due to a temporary boost from U.S. tariffs on cars [4]. - The unexpected departure of CEO Bill Nash on November 6, 2025, is also under investigation to determine if CarMax adequately assessed its portfolio of car loans [5]. Group 3: Stock Performance - On September 25, 2025, CarMax reported disappointing financial results, including a 5.4% decline in retail used unit sales and a net income drop from $132.8 million to approximately $95.4 million year-over-year [6]. - Following the financial report, CarMax's stock price fell by $11.45, or about 20%, from $57.05 to $45.60 per share [7]. - The announcement of CEO Bill Nash's departure and a weak preliminary Q3 2025 outlook led to an additional stock price drop of over 24% [7].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Eastern District of Virginia, titled MacMahon v. Stride, Inc., et al., No. 1:25-cv-02019 [3]. - Investors have until January 12, 2026, to request to be appointed to lead the case [3]. Group 2: Allegations Against Stride - Stride is accused of inflating enrollment numbers by retaining "ghost students" and failing to comply with employee background checks and licensure laws [4][5]. - The company claimed to experience growth and high demand for its services, which is contradicted by the allegations of poor customer experience leading to higher withdrawal rates and lower conversion rates [4]. Group 3: Stock Performance Impact - On September 14, 2025, a report of the lawsuit caused Stride's stock to drop by $18.60 per share, over 11%, from $158.36 to $139.76 [5]. - Following Stride's admission of poor customer experience on October 28, 2025, the stock plummeted by $83.48 per share, more than 54%, from $153.53 to $70.05 [6].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics and certain senior executives for potential violations of federal securities laws, with a legal deadline for investors to act by December 15, 2025 [2][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [5]. Allegations and Clinical Data - The lawsuit alleges that MoonLake misrepresented its clinical data and the advantages of SLK's Nanobody structure compared to traditional monoclonal antibody treatments, which may have misled investors regarding the drug's regulatory approval and commercial viability [6][7]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [8].